Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE6.5900
- TODAY'S CHANGE (%)-0.7300 (-9.9727%)
- Bid / Lots5.7400/ 1
- Ask / Lots8.0000/ 1
- Open / Previous Close7.2800 / 7.3200
- Day Range
- 52 Week Range
- Volume328,874
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 3034 | 7.315 |
| 09:34 ET | 100 | 7.315 |
| 09:38 ET | 100 | 7.3499 |
| 09:39 ET | 1057 | 7.31 |
| 09:45 ET | 100 | 7.4 |
| 09:54 ET | 10172 | 7.28 |
| 09:56 ET | 140 | 7.26 |
| 09:57 ET | 100 | 7.26 |
| 10:01 ET | 100 | 7.26 |
| 10:03 ET | 9294 | 7.21 |
| 10:06 ET | 5901 | 7.18 |
| 10:08 ET | 1271 | 7.24 |
| 10:10 ET | 200 | 7.18 |
| 10:12 ET | 400 | 7.215 |
| 10:14 ET | 458 | 7.215 |
| 10:17 ET | 1871 | 7.185 |
| 10:19 ET | 100 | 7.16 |
| 10:21 ET | 10107 | 7.08 |
| 10:24 ET | 37736 | 6.9999 |
| 10:26 ET | 300 | 6.9 |
| 10:28 ET | 8276 | 6.9092 |
| 10:30 ET | 1863 | 6.91 |
| 10:32 ET | 378 | 6.9 |
| 10:33 ET | 2075 | 6.88 |
| 10:35 ET | 300 | 6.87 |
| 10:37 ET | 1223 | 6.91 |
| 10:39 ET | 328 | 6.94 |
| 10:42 ET | 575 | 6.9565 |
| 10:44 ET | 1069 | 6.9121 |
| 10:51 ET | 4489 | 6.8692 |
| 10:53 ET | 1600 | 6.82 |
| 10:55 ET | 300 | 6.82 |
| 10:57 ET | 400 | 6.835 |
| 11:00 ET | 100 | 6.82 |
| 11:02 ET | 100 | 6.82 |
| 11:04 ET | 2258 | 6.8 |
| 11:06 ET | 200 | 6.76 |
| 11:13 ET | 300 | 6.77 |
| 11:15 ET | 744 | 6.78 |
| 11:20 ET | 100 | 6.79 |
| 11:22 ET | 1924 | 6.9 |
| 11:24 ET | 547 | 6.9095 |
| 11:27 ET | 200 | 6.87 |
| 11:29 ET | 100 | 6.875 |
| 11:31 ET | 1146 | 6.826 |
| 11:33 ET | 200 | 6.78 |
| 11:36 ET | 200 | 6.78 |
| 11:38 ET | 1620 | 6.73 |
| 11:47 ET | 2610 | 6.735 |
| 11:49 ET | 100 | 6.7334 |
| 12:02 ET | 500 | 6.7596 |
| 12:03 ET | 100 | 6.7599 |
| 12:05 ET | 100 | 6.73 |
| 12:09 ET | 2700 | 6.69 |
| 12:18 ET | 1137 | 6.7043 |
| 12:20 ET | 1931 | 6.679 |
| 12:21 ET | 200 | 6.68 |
| 12:23 ET | 630 | 6.6776 |
| 12:25 ET | 300 | 6.69 |
| 12:27 ET | 1100 | 6.71 |
| 12:34 ET | 1733 | 6.701 |
| 12:36 ET | 400 | 6.71 |
| 12:41 ET | 2150 | 6.7199 |
| 12:43 ET | 250 | 6.7178 |
| 12:45 ET | 1041 | 6.7 |
| 12:50 ET | 700 | 6.68 |
| 12:57 ET | 500 | 6.67 |
| 12:59 ET | 1000 | 6.68 |
| 01:03 ET | 200 | 6.68 |
| 01:06 ET | 683 | 6.65 |
| 01:10 ET | 100 | 6.62 |
| 01:12 ET | 100 | 6.62 |
| 01:15 ET | 2153 | 6.59 |
| 01:17 ET | 1045 | 6.6199 |
| 01:19 ET | 7280 | 6.74 |
| 01:21 ET | 1930 | 6.75 |
| 01:24 ET | 300 | 6.75 |
| 01:26 ET | 200 | 6.75 |
| 01:28 ET | 679 | 6.71 |
| 01:30 ET | 100 | 6.73 |
| 01:32 ET | 600 | 6.73 |
| 01:35 ET | 585 | 6.77 |
| 01:37 ET | 2794 | 6.79 |
| 01:39 ET | 800 | 6.85 |
| 01:42 ET | 1000 | 6.87 |
| 01:44 ET | 3785 | 6.87 |
| 01:46 ET | 10061 | 6.75 |
| 01:50 ET | 129 | 6.6837 |
| 01:51 ET | 200 | 6.69 |
| 01:55 ET | 711 | 6.63 |
| 01:57 ET | 25988 | 6.73 |
| 02:02 ET | 300 | 6.6 |
| 02:04 ET | 100 | 6.6 |
| 02:06 ET | 5700 | 6.71 |
| 02:11 ET | 100 | 6.67 |
| 02:13 ET | 1100 | 6.69 |
| 02:15 ET | 400 | 6.66 |
| 02:24 ET | 500 | 6.66 |
| 02:29 ET | 2400 | 6.68 |
| 02:31 ET | 1628 | 6.704 |
| 02:38 ET | 100 | 6.67 |
| 02:40 ET | 100 | 6.65 |
| 02:42 ET | 300 | 6.67 |
| 02:56 ET | 400 | 6.69 |
| 02:58 ET | 100 | 6.67 |
| 03:12 ET | 750 | 6.65 |
| 03:14 ET | 200 | 6.61 |
| 03:18 ET | 2122 | 6.65 |
| 03:20 ET | 100 | 6.65 |
| 03:21 ET | 300 | 6.65 |
| 03:25 ET | 709 | 6.66 |
| 03:27 ET | 1450 | 6.663 |
| 03:30 ET | 150 | 6.675 |
| 03:32 ET | 2218 | 6.69 |
| 03:34 ET | 200 | 6.67 |
| 03:36 ET | 100 | 6.67 |
| 03:38 ET | 100 | 6.67 |
| 03:39 ET | 3218 | 6.67 |
| 03:41 ET | 2964 | 6.665 |
| 03:43 ET | 1100 | 6.6797 |
| 03:45 ET | 2000 | 6.67 |
| 03:48 ET | 748 | 6.66 |
| 03:50 ET | 4590 | 6.6499 |
| 03:52 ET | 2020 | 6.63 |
| 03:54 ET | 1638 | 6.62 |
| 03:56 ET | 7341 | 6.62 |
| 03:57 ET | 3181 | 6.6 |
| 03:59 ET | 12059 | 6.59 |
Yesterday
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Press Release: Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow JonesAdverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 136.8M | -0.6x | --- |
Omega Therapeutics Inc | 122.4M | -1.3x | --- |
Sagimet Biosciences Inc | 126.1M | -3.2x | --- |
Adlai Nortye Ltd | 124.4M | -0.5x | --- |
Kodiak Sciences Inc | 137.1M | -0.6x | --- |
Yubo International Biotech Ltd | 130.6M | -103.9x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Medical Officer
- Rabia Ozden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $136.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
